OBJECTIVES: Our previous studies have demonstrated that the Damage Associated Molecular Pattern (DAMP) protein, S100A4, is overexpressed in the involved skin and peripheral blood of patients with SSc. It is associated with skin and lung involvement, and disease activity. By contrast, lack of S100A4 prevented the development of experimental dermal fibrosis. Herein we aimed to evaluate the effect of murine anti-S100A4 mAb 6B12 in the treatment of preestablished experimental dermal fibrosis. METHODS: The effects of 6B12 were assessed at therapeutic dosages in a modified bleomycin-induced dermal fibrosis mouse model by evaluating fibrotic (dermal thickness, proliferation of myofibroblasts, hydroxyproline content, phosphorylated Smad3-positive cell count) and inflammatory (leukocytes infiltrating the lesional skin, systemic levels of selected cytokines and chemokines) outcomes, and transcriptional profiling (RNA sequencing). RESULTS: Treatment with 7.5 mg/kg 6B12 attenuated and might even reduce pre-existing dermal fibrosis induced by bleomycin as evidenced by reduction in dermal thickness, myofibroblast count and collagen content. These antifibrotic effects were mediated by the downregulation of TGF-β/Smad signalling and partially by reducing the number of leukocytes infiltrating the lesional skin and decrease in the systemic levels of IL-1α, eotaxin, CCL2 and CCL5. Moreover, transcriptional profiling demonstrated that 7.5 mg/kg 6B12 also modulated several profibrotic and proinflammatory processes relevant to the pathogenesis of SSc. CONCLUSION: Targeting S100A4 by the 6B12 mAb demonstrated potent antifibrotic and anti-inflammatory effects on bleomycin-induced dermal fibrosis and provided further evidence for the vital role of S100A4 in the pathophysiology of SSc.

1st Faculty of Medicine Charles University Prague Czech Republic

Agiana Pharmaceuticals Oslo Norway

Arxx Therapeutics Oslo Norway

Clinic for Rheumatology University Hospital Düsseldorf Medical Faculty of Heinrich Heine University Düsseldorf Germany

Department of Physiotherapy Faculty of Physical Education and Sport Charles University Prague Czech Republic

Department of Rheumatology 1st Faculty of Medicine Charles University Prague Czech Republic

Hiller Research Center University Hospital Düsseldorf Medical Faculty of Heinrich Heine University Düsseldorf Germany

Institute of Rheumatology Prague Czech Republic

Zobrazit více v PubMed

Denton CP, Khanna D.. Systemic sclerosis. Lancet 2017;390:1685–99. PubMed

Stern EP, Denton CP.. The pathogenesis of systemic sclerosis. Rheum Dis Clin North Am 2015;41:367–82. PubMed

Bukiri H, Volkmann ER.. Current advances in the treatment of systemic sclerosis. Curr Opin Pharmacol 2022;64:102211. PubMed PMC

Distler JHW, Feghali-Bostwick C, Soare A. et al. Review: frontiers of antifibrotic therapy in systemic sclerosis. Arthritis Rheumatol 2017;69:257–67. Feb PubMed

Rosendahl AH, Schönborn K, Krieg T.. Pathophysiology of systemic sclerosis (scleroderma). Kaohsiung J Med Sci 2022;38:187–95. PubMed PMC

Pattanaik D, Brown M, Postlethwaite BC, Postlethwaite AE.. Pathogenesis of systemic sclerosis. Front Immunol 2015;6:272. PubMed PMC

Distler JHW, Györfi AH, Ramanujam M. et al. Shared and distinct mechanisms of fibrosis. Nat Rev Rheumatol 2019;15:705–30. PubMed

Raja J, Denton CP.. Cytokines in the immunopathology of systemic sclerosis. Semin Immunopathol 2015;37:543–57. PubMed

King J, Abraham D, Stratton R.. Chemokines in systemic sclerosis. Immunol Lett 2018;195:68–75. PubMed

Li Z, Li Y, Liu S, Qin Z.. Extracellular S100A4 as a key player in fibrotic diseases. J Cell Mol Med 2020;24:5973–83. PubMed PMC

Cerezo LA, Remáková M, Tomčik M. et al. The metastasis-associated protein S100A4 promotes the inflammatory response of mononuclear cells via the TLR4 signalling pathway in rheumatoid arthritis. Rheumatology (Oxford) 2014;53:1520–6. PubMed

Fei F, Qu J, Li C. et al. Role of metastasis-induced protein S100A4 in human non-tumor pathophysiologies. Cell Biosci 2017;7:64. PubMed PMC

Neidhart M, Pajak A, Laskari K. et al. Oligomeric S100A4 is associated with monocyte innate immune memory and bypass of tolerance to subsequent stimulation with lipopolysaccharides. Front Immunol 2019;10:791. PubMed PMC

Dahlmann M, Okhrimenko A, Marcinkowski P. et al. RAGE mediates S100A4-induced cell motility via MAPK/ERK and hypoxia signaling and is a prognostic biomarker for human colorectal cancer metastasis. Oncotarget 2014;5:3220–33. PubMed PMC

Medapati MR, Dahlmann M, Ghavami S. et al. RAGE mediates the pro-migratory response of extracellular S100A4 in human thyroid cancer cells. Thyroid 2015;25:514–27. PubMed

Tomcik M, Palumbo-Zerr K, Zerr P. et al. S100A4 amplifies TGF-β-induced fibroblast activation in systemic sclerosis. Ann Rheum Dis 2015;74:1748–55. Sep PubMed

Štorkánová H, Cerezo LA, Oreska S. et al. Ab0410 S100a4 plasma levels correlate with disease activity, skin fibrosis and interstitial lung disease in systemic sclerosis patients. Ann Rheum Dis 2021;80:1233.

Klingelhöfer J, Grum-Schwensen B, Beck MK. et al. Anti-S100A4 antibody suppresses metastasis formation by blocking stroma cell invasion. Neoplasia 2012;14:1260–8. Dec PubMed PMC

Beyer C, Schett G, Distler O, Distler JHW.. Animal models of systemic sclerosis: prospects and limitations. Arthritis Rheum 2010;62:2831–44. PubMed

Štorkánová H, Štorkánová L, Navrátilová A. et al. Inhibition of Hsp90 counteracts the established experimental dermal fibrosis induced by bleomycin. Biomedicines 2021;9:650. PubMed PMC

Avouac J, Fürnrohr BG, Tomcik M. et al. Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis. Arthritis Rheum 2011;63:800–9. PubMed

Woessner JF. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys 1961;93:440–7. PubMed

Kropáčková T, Vernerová L, Štorkánová H. et al. Clusterin is upregulated in serum and muscle tissue in idiopathic inflammatory myopathies and associates with clinical disease activity and cytokine profile. Clin Exp Rheumatol 2021;39:1021–32. PubMed

R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2020.

Ritchie ME, Phipson B, Wu D. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 2015;43:e47. PubMed PMC

Yu G, Wang LG, Han Y, He QY.. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics J Integr Biol 2012;16:284–7. PubMed PMC

Hinchcliff M, Huang CC, Wood TA. et al. Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis. J Invest Dermatol 2013;133:1979–89. PubMed PMC

Bresnick AR. S100 proteins as therapeutic targets. Biophys Rev 2018;10:1617–29. PubMed PMC

Prescott RJ, Freemont AJ, Jones CJ, Hoyland J, Fielding P.. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 1992;166:255–63. PubMed

Boye K, Maelandsmo GM.. S100A4 and metastasis: a small actor playing many roles. Am J Pathol 2010;176:528–35. PubMed PMC

Fei F, Qu J, Zhang M, Li Y, Zhang S.. S100A4 in cancer progression and metastasis: a systematic review. Oncotarget 2017;8:73219–39. PubMed PMC

Mishra SK, Siddique HR, Saleem M.. S100A4 calcium-binding protein is key player in tumor progression and metastasis: preclinical and clinical evidence. Cancer Metastasis Rev 2012;31:163–72. PubMed

Ambartsumian N, Klingelhöfer J, Grigorian M.. The multifaceted S100A4 protein in cancer and inflammation. Methods Mol Biol 2019;1929:339–65. PubMed

Li Y, Bao J, Bian Y. et al. S100A4+ macrophages are necessary for pulmonary fibrosis by activating lung fibroblasts. Front Immunol 2018;9:1776. PubMed PMC

Wen J, Jiao B, Tran M, Wang Y.. Pharmacological inhibition of S100A4 attenuates fibroblast activation and renal fibrosis. Cells 2022;11:2762. PubMed PMC

Laffan SB, Thomson AS, Mai S. et al. Immune complex disease in a chronic monkey study with a humanised, therapeutic antibody against CCL20 is associated with complement-containing drug aggregates. PLoS One 2020;15:e0231655. PubMed PMC

Tomčík M, Trinh-Minh T, Manh CT. et al. Op0245 anti-S100A4 monoclonal antibody treatment ameliorates skin fibrosis in inflammatory and non-inflammatory pre-clinical models of systemic sclerosis. Ann Rheum Dis 2021;80:150

Chakraborty D, Šumová B, Mallano T. et al. Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis. Nat Commun 2017;8:1130. PubMed PMC

Zehender A, Huang J, Györfi AH. et al. The tyrosine phosphatase SHP2 controls TGFβ-induced STAT3 signaling to regulate fibroblast activation and fibrosis. Nat Commun 2018;9:3259. PubMed PMC

Dees C, Pötter S, Zhang Y. et al. TGF-β–induced epigenetic deregulation of SOCS3 facilitates STAT3 signaling to promote fibrosis. J Clin Invest 2020;130:2347–63. PubMed PMC

Kawaguchi Y, Hara M, Wright TM.. Endogenous IL-1α from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. J Clin Invest 1999;103:1253–60. PubMed PMC

Kawaguchi Y, McCarthy SA, Watkins SC, Wright TM.. Autocrine activation by interleukin 1alpha induces the fibrogenic phenotype of systemic sclerosis fibroblasts. J Rheumatol 2004;31:1946–54. PubMed

Distler JHW, Akhmetshina A, Schett G, Distler O.. Monocyte chemoattractant proteins in the pathogenesis of systemic sclerosis. Rheumatology (Oxford) 2009;48:98–103. PubMed

Bandinelli F, Del Rosso A, Gabrielli A. et al. CCL2, CCL3 and CCL5 chemokines in systemic sclerosis: the correlation with SSc clinical features and the effect of prostaglandin E1 treatment. Clin Exp Rheumatol 2012;30(2 Suppl 71):S44–9. PubMed

Zhu HL, Du Q, Chen WL. et al. Altered serum cytokine expression profile in systemic sclerosis and its regulatory mechanisms. Beijing Da Xue Xue Bao 2019;51:716–22. PubMed PMC

Piera-Velazquez S, Jimenez SA.. Oxidative stress induced by reactive oxygen species (ROS) and NADPH Oxidase 4 (NOX4) in the pathogenesis of the fibrotic process in systemic sclerosis: a promising therapeutic target. J Clin Med 2021;10:4791. PubMed PMC

Dosoki H, Stegemann A, Taha M. et al. Targeting of NADPH oxidase in vitro and in vivo suppresses fibroblast activation and experimental skin fibrosis. Exp Dermatol 2017;26:73–81. PubMed